Cesca Therapeutics trades as part of the medical devices industry and trades as part of the healthcare sector. The company CEO is Xiaochun Chris Xu. Cesca Therapeutics Inc is engaged in the development and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
Previous Intraday Performance:
The KOOL shares had a previous change of -5.26% which opened at 3.38 and closed at 3.24. It moved to an intraday high of 3.99 and a low of 3.06.
Over the last five trading days, KOOL shares returned 10.58% and in the past 30 trading days it returned 19.07%. Over three months, it changed -7.43%. In one year it has changed -40.90% and within that year its 52 week high was 5.70 and its 52 week low was 2.10. KOOL stock is 54.29% above its 52 week low.
Our calculations result in a 200 day moving average of 3.24 and a 50 day moving average of 2.80. Right now, KOOL stock is trading -0.12% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.
The company has a market cap of $7.7m with 2.4m shares outstanding and a float of 2.4m shares. Trading volume was 248,782 shares and has experienced an average volume of 76,337 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Cesca Therapeutics was -22.7 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.08.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr 2019||Reported 05-14-2019:||-0.80|
|4th||Qtr 2018||Reported 03-25-2019:||-1.50|
|3rd||Qtr 2018||Reported 11-14-2018:||-1.20|
|2nd||Qtr 2018||Reported 08-13-2018:||-17.30|
|1st||Qtr 2018||Reported 05-14-2018:||-2.70|
The growth of the EPS is critical in understanding the current valuation of Cesca Therapeutics; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -55.70% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 2.10% of institutional ownership.
The beta was calculated to be 1.05.
SeekingAlpha: Intra-Cellular Therapies beats by $0.24
Based on last reported financials, the company’s return on assets is -125.95%, price-to-sales is 0.75 and price-to-book is 1.52.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
2 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result